Zynerba Pharmaceuticals Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Armando Anido
Chief executive officer
US$1.9m
Total compensation
| CEO salary percentage | 33.6% |
| CEO tenure | 9yrs |
| CEO ownership | 1.9% |
| Management average tenure | 6.8yrs |
| Board average tenure | 8.2yrs |
Recent management updates
Recent updates
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?
Mar 01
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
Nov 11Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome
Oct 06Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01
Aug 10We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
Jul 22Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital
Jul 21Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation
Mar 23We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
Dec 02We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
May 27Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome
Dec 17Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
Nov 23
Zynerba Pharmaceuticals EPS beats by $0.12
Nov 09Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback
Oct 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$38m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$2m | US$633k | -US$35m |
| Sep 30 2022 | n/a | n/a | -US$36m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$38m |
| Dec 31 2021 | US$2m | US$603k | -US$37m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$37m |
| Mar 31 2021 | n/a | n/a | -US$47m |
| Dec 31 2020 | US$1m | US$585k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$52m |
| Jun 30 2020 | n/a | n/a | -US$45m |
| Mar 31 2020 | n/a | n/a | -US$36m |
| Dec 31 2019 | US$1m | US$568k | -US$33m |
| Sep 30 2019 | n/a | n/a | -US$30m |
| Jun 30 2019 | n/a | n/a | -US$36m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$2m | US$568k | -US$40m |
| Sep 30 2018 | n/a | n/a | -US$40m |
| Jun 30 2018 | n/a | n/a | -US$41m |
| Mar 31 2018 | n/a | n/a | -US$37m |
| Dec 31 2017 | US$2m | US$552k | -US$32m |
| Sep 30 2017 | n/a | n/a | -US$31m |
| Jun 30 2017 | n/a | n/a | -US$28m |
| Mar 31 2017 | n/a | n/a | -US$26m |
| Dec 31 2016 | US$901k | US$536k | -US$23m |
Compensation vs Market: Armando's total compensation ($USD1.88M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Armando's compensation has been consistent with company performance over the past year.
CEO
Armando Anido (65 yo)
9yrs
Tenure
US$1,881,402
Compensation
Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been an Independent Director of SCYNEXIS, Inc. since January 21,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 9yrs | US$1.88m | 1.94% $ 1.3m | |
| President | 9yrs | US$1.38m | 1.18% $ 775.1k | |
| CFO & VP of Corporate Development (Leave of Absence) | 7.1yrs | US$1.26m | 0.75% $ 491.5k | |
| VP, Corporate Controller & Interim CFO | 6.6yrs | no data | 0.17% $ 111.2k | |
| Chief Legal Officer & Corporate Secretary | 1.7yrs | no data | 0.45% $ 295.1k | |
| Vice President of Human Resources | 5.6yrs | no data | no data |
6.8yrs
Average Tenure
59yo
Average Age
Experienced Management: ZYNE's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 9yrs | US$1.88m | 1.94% $ 1.3m | |
| Independent Director | 8.2yrs | US$107.50k | 0.15% $ 98.5k | |
| Independent Director | 8.2yrs | US$105.00k | 0.15% $ 98.5k | |
| Lead Independent Director | 8.2yrs | US$135.00k | 0.15% $ 98.5k | |
| Independent Director | 5.5yrs | US$102.50k | 0.16% $ 105.0k | |
| Independent Director | 8.2yrs | US$110.00k | 0.15% $ 98.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 7yrs | no data | no data | |
| Independent Director | 4.7yrs | US$100.00k | 0.15% $ 98.5k | |
| Member of Scientific Advisory Board | no data | no data | no data |
8.2yrs
Average Tenure
65yo
Average Age
Experienced Board: ZYNE's board of directors are considered experienced (8.2 years average tenure).